Breast Cancer Ductal Carcinoma Caused by Zantac and Ranitidine
Drug Liability Attorneys in New York for Breast Cancer - Call (888) 260-0473
Have you used recalled Zantac or Ranitidine and been recently diagnosed with breast cancer? A 2008 medical study linked Zantac to an increase in breast ductal carcinoma.[i] You can contact our firm and ask questions about this very new medical development and learn about your potential rights. The online Valisure Pharmacy, with Stanford University, published a major report on the cancers associated with Zantac and oncologist Dr. Lior Braunstein studies Zantac use and cancer at Memorial Sloan Kettering.
The leading cause of the recall was the carcinogen N-Nitrosodimethylamine (NDMA) being found within the drugs, or created by digestive actions. NDMA is a known carcinogen which has strict limits for daily intake. NDMA is “genotoxic,” meaning that enters cellular DNA and can cause immediate cancerous growth. At Rheingold Giuffra Ruffo & Plotkin LLP, our New York defective drug lawyers handle cases directly and do not refer them to other firms.
New York City Attorneys Speaking with Zantac and Ranitidine Users & Filing Cancer Lawsuits
Have you been diagnosed with breast cancer after prolonged use of these drugs? A 2008 study suggests there is a positive correlation between NDMA use and the formation of breast cancer. The study found “Current users of ranitidine had a 2.2-fold increased risk of ductal carcinoma that was confined to a 2.4-fold increased risk of estrogen receptor-positive/progesterone receptor-positive ductal carcinoma.”
You may be able to file a cancer lawsuit if you developed cancer while consuming these drugs for a prolonged period of time. Use the contact form on this page for a free case evaluation by one of our experienced dangerous drug attorneys. You may also call our office directly at (888) 260-0473 to discuss your drug cancer lawsuit and possible settlement. At Rheingold Giuffra Ruffo & Plotkin LLP, our New York defective drug lawyers handle cases directly and do not refer them to other firms.
What Are the Signs of Invasive Ductal Breast Carcinoma and Hormone Receptor-Positive Ductal Carcinoma?
Ductal carcinoma begins by invading milk ducts in the breast. This can be diagnosed as invasive or intraductal carcinoma.[ii] Hormone-receptor positive breast cancer is a tumor which can be actuated by estrogen and progesterone.[iii]
Common signs of these breast cancers may include:
The exact cause of these cancers was not part of the 2008 study, but we do know that Zantac contains and creates a carcinogenic compound N-Nitrosodimethylamine (NDMA), which was invented as rocket fuel. Of note, the cancer risk was well documented in the Valusire Citizen’s Petition[iv] which resulted in Zantac and Ranitidine being removed from the shelves around the world.
Our New York dangerous drug lawyers perform a rigorous investigation of the impact this injury has had on clients and their families, both medically and financially. We have access to expert witnesses in pharmacology and other relevant fields who help us determine how dangerous drugs contributed to your injuries and who is liable for the damages. We offer every client personal, individual and attentive client service and dedication to results. Furthermore, through our extensive litigation against pharmaceutical companies, we are experienced with lawsuits involving dangerous drugs, and filing lawsuits in state and federal courts.
Our New York defective drug attorneys are able to handle a wide range of drug liability claims, including those involving these medications. Call (888) 260-0473 for a free case evaluation.
Auto Accident $2,750,000
Biopsy Resulting In Blindness $2,500,000
Birth Injury $1,000,000
Brain Damage $12,000,000
Brain Damage of Infant $1,000,000
Brain Damage of Infant $2,100,000
Cancer Misdiagnosis $2,500,000
Cardiovascular Injury $2,200,000
Cataract Surgery Complication $1,700,000
Child's Hand Injury $9,000,000